ALGSAligos Therapeutics, Inc.

$45M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$169,000-73.1% YoY

Gross Profit

-$88,000-52.1% margin

Operating Income

-$22M-12907.7% margin

Net Income

-$20M-11763.9% margin

EPS (Diluted)

$-1.91

QoQ Revenue Growth

-77.2%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$90M

Total Liabilities

$36M

Stockholders' Equity

$54M

Cash & Equivalents

$18M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$169,000	$629,000	-73.1%
Gross Profit	-$88,000	$629,000	-114.0%
Operating Income	-$22M	-$21M	-6.1%
Net Income	-$20M	-$82M	+75.8%

ALGS Q4 2025 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena